Shilpa Medicare Ltd
NSE:SHILPAMED
Shilpa Medicare Ltd
PP&E Net
Shilpa Medicare Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shilpa Medicare Ltd
NSE:SHILPAMED
|
PP&E Net
₹16.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
PP&E Net
₹85.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
PP&E Net
₹62.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
PP&E Net
₹112.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
PP&E Net
₹36.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
PP&E Net
₹31.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shilpa Medicare Ltd
Glance View
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
See Also
What is Shilpa Medicare Ltd's PP&E Net?
PP&E Net
16.2B
INR
Based on the financial report for Dec 31, 2024, Shilpa Medicare Ltd's PP&E Net amounts to 16.2B INR.
What is Shilpa Medicare Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
14%
Over the last year, the PP&E Net growth was 5%. The average annual PP&E Net growth rates for Shilpa Medicare Ltd have been 7% over the past three years , 11% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet